We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-2.68%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.3B
AUM Growth
-$1.1B
Cap. Flow
-$283M
Cap. Flow %
-1.64%
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
21
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$42.9M
2
ROIV icon
Roivant Sciences
ROIV
+$41.6M
3
ABCL icon
AbCellera Biologics
ABCL
+$40.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.6M
5
IMGN
Immunogen Inc
IMGN
+$17.9M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$469M
2
KYNB
Kyntra Bio
KYNB
+$39.7M
3
BPMC
Blueprint Medicines
BPMC
+$15M
4
KRYS icon
Krystal Biotech
KRYS
+$13.6M
5
VSTM icon
Verastem
VSTM
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SANA icon
51
Sana Biotechnology
SANA
$882M
$11.9M 0.07%
2,000,000
– –
COGT icon
52
Cogent Biosciences
COGT
$6.76B
$11.6M 0.07%
+979,600
New +$11.2M
PNT
53
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$10.6M 0.06%
1,169,103
– –
ADAP
54
DELISTED
Adaptimmune Therapeutics
ADAP
$10.1M 0.06%
10,969,282
+1,138,405
+12% +$1.36M
NVTA
55
DELISTED
Invitae Corporation
NVTA
$10M 0.06%
8,881,104
– –
VSTM icon
56
Verastem
VSTM
$528M
$9.94M 0.06%
1,336,485
-790,302
-37% -$5.48M
GERN icon
57
Geron
GERN
$898M
$9.83M 0.06%
3,061,224
– –
HRTX icon
58
Heron Therapeutics
HRTX
$93.4M
$9.43M 0.05%
8,131,678
– –
LONA
59
LeonaBio Inc
LONA
$66.1M
$9.3M 0.05%
315,381
+80,345
+34% +$2.29M
RNAM
60
DELISTED
Avidity Biosciences
RNAM
$8.87M 0.05%
799,451
-204,600
-20% -$2.57M
BLUE
61
DELISTED
bluebird bio
BLUE
$8.22M 0.05%
124,986
– –
FATE icon
62
Fate Therapeutics
FATE
$275M
$7.96M 0.05%
1,671,717
– –
ALLO icon
63
Allogene Therapeutics
ALLO
$625M
$7.84M 0.05%
1,576,901
– –
OPT
64
DELISTED
Opthea Limited American Depositary Shares
OPT
$7.54M 0.04%
2,691,391
– –
INSM icon
65
Insmed
INSM
$22.4B
$7.24M 0.04%
343,000
– –
TCRX icon
66
TScan Therapeutics
TCRX
$48.5M
$6.96M 0.04%
2,784,792
– –
WHWK
67
Whitehawk Therapeutics
WHWK
$181M
$6.77M 0.04%
989,928
– –
SERA icon
68
Sera Prognostics
SERA
$80.3M
$5.86M 0.03%
1,777,435
-11,565
-0.6% -$39.7K
ALEC icon
69
Alector
ALEC
$169M
$5.8M 0.03%
964,851
– –
CMPX icon
70
Compass Therapeutics
CMPX
$349M
$4.95M 0.03%
1,557,630
– –
NTRA icon
71
Natera
NTRA
$36.4B
$4.87M 0.03%
100,000
– –
MGNX icon
72
MacroGenics
MGNX
$233M
$4.78M 0.03%
892,579
– –
MREO
73
Mereo BioPharma
MREO
$48.9M
$4.69M 0.03%
+3,554,979
New +$4.12M
ARAV
74
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.11M 0.02%
3,261,224
– –
AFMD
75
DELISTED
Affimed
AFMD
$3.95M 0.02%
659,683
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Baker Bros. Advisors held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
  • Baker Bros. Advisors added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
  • Baker Bros. Advisors's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
  • Baker Bros. Advisors fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
  • Baker Bros. Advisors opened 6 new positions and closed 5 in Q2 2023.
  • Baker Bros. Advisors's portfolio value fell 6% quarter-over-quarter to $17.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.